|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61P 29/00 | (2018.01) |
| A61K 31/4184 | (2006.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61P 9/14 | (2018.01) | ||
| A61P 19/02 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61K 31/4184 | (2013.01) | ||
| C07D 471/04 | (2013.01) | ||
| A61K2039/505 | (2013.01) | ||
| C07K 16/2887 | (2013.01) | ||
| C07K2317/24 | (2013.01) | ||
| A61K 39/39558 | (2013.01) | ||
| A61K 31/496 | (2013.01) | ||
| A61K 31/675 | (2013.01) | ||
| A61K 31/704 | (2013.01) | ||
| A61K 31/475 | (2013.01) | ||
| A61K 31/573 | (2013.01) |
| (11) | Patento numeris | 3672591 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 19845466.2 |
| Europos patento paraiškos padavimo data | 2019-07-22 | |
| (97) | Europos patento paraiškos paskelbimo data | 2020-07-01 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2024-02-14 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/CN2019/097028 |
| Data | 2019-07-22 |
| (87) | Numeris | WO 2020/024826 |
| Data | 2020-02-06 |
| (30) | Numeris | Data | Šalis |
| 201810867252 | 2018-07-31 | CN |
| (72) |
YANG, Dajun , CN
ZHAI, Yifan , CN
WANG, Guangfeng , CN
|
| (73) |
Ascentage Pharma (Suzhou) Co., Ltd. ,
Unit 701, Building B7, 218 Xinghu Street
Suzhou Industrial Park, Suzhou, Jiangsu 215000,
CN
|
| (54) | SYNERGISTIC ANTITUMOR EFFECT OF BCL-2 INHIBITOR COMBINED WITH RITUXIMAB AND/OR BENDAMUSTINE OR BCL-2 INHIBITOR COMBINED WITH CHOP |
| SYNERGISTIC ANTITUMOR EFFECT OF BCL-2 INHIBITOR COMBINED WITH RITUXIMAB AND/OR BENDAMUSTINE OR BCL-2 INHIBITOR COMBINED WITH CHOP |